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Summary 
Effective treatments for patients with castration-resistant prostate cancer (CRPC) have not 
yet been established. Novel approaches for identification of putative therapeutic targets for 
CRPC are needed. Analyses of RNA-sequencing of microRNA (miRNA) expression revealed 
that miR-99a-3p (passenger strand) is significantly downregulated in several types of cancers. 
Here, we aimed to identify novel miR-99a-3p regulatory networks and therapeutic targets for 
CRPC. Ectopic expression of miR-99a-3p significantly inhibited cancer cell proliferation, 
migration, and invasion in PCa cells. Non-SMC condensin I complex subunit G (NCAPG) was a 
direct target of miR-99a-3p in PCa cells. Overexpression of NCAPG was detected in CRPC 
clinical specimens and was significantly associated with shorter disease-free survival and 
advanced clinical stage. Knockdown of NCAPG inhibited cancer cell aggressiveness. The 
passenger strand miR-99a-3p acted as an antitumor miRNA in naïve PCa and CRPC. NCAPG 
was regulated by miR-99a-3p, and its overexpression was involved in CRPC pathogenesis. 
Involvement of passenger strand of miRNA in cancer pathogenesis is novel concept and 
identification of antitumor miRNA regulatory networks in CRPC might be provided novel 
prognostic markers and therapeutic targets for this disease. 
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Introduction 
In developed countries, prostate cancer (PCa) is one of the most commonly diagnosed 
cancers, identified by prostate-specific antigen (PSA) screening; PCa is also the third leading 
cause of cancer-related death among men (1). Most naïve PCa initially responds well to 
androgen-deprivation therapy (ADT). However, during ADT treatment, PCa cells acquire ADT 
treatment resistance and progress to a lethal pathology known as castration-resistant prostate 
cancer (CRPC) (2). Cancer cells that have reached CRPC can cause distant metastasis, and 
effective treatments for patients with CRPC have not yet been established (3). Identification of 
the molecular pathogenesis underlying acquisition of androgen-independent and metastatic 
signaling pathways based on advanced genomic approaches is essential for further 
understanding of this disease.  
MicroRNAs (miRNAs) are endogenous small RNA (molecules 18-23 bases in length) that 
act as central players regulating the expression control of protein-coding and protein-noncoding 
RNAs (4, 5). Interestingly, a single miRNA can directly regulate a vast number of RNAs in 
human cells (6). Therefore, aberrant expression of miRNAs can disrupt normal control of RNA 
expression in cancer cells. Furthermore, dysregulation of miRNAs is contributed to cancer cell 
malignancies, such as progression, metastasis, and treatment resistance (7-10).  
Analysis of our original miRNA expression signature of cancers based on RNA-
sequencing revealed that several passenger strands of miRNAs, e.g., miR-145-3p, miR-150-3p, 
miR-149-3p, miR-199a-3p, and miR-144-5p, are downregulated in several cancer tissues and act 
as antitumor miRNAs in cancer cells (11-15). However, this is inconsistent with the paradigm 
that the guide strand of miRNA is loaded into the miRNA-induced silencing complex (RISC) 
and represses translation or degradation of target genes (16), whereas the passenger strand of 
miRNA is thought to be destroyed in the cytoplasm and to have no function (17-19).  
We have sequentially identified the functional significance of passenger strands of 
miRNAs in cancer cells based on miRNA signatures (11-15). In this study, we focused on miR-
99a-5p (guide strand) whose expression was significantly downregulated in our miRNA 
signature of metastatic CRPC (15), and investigated the functional roles including passenger 
strand miR-99a-3p in naïve PCa and CRPC cells. Previous studies have shown that the guide 
strand miR-99a-5p has antitumor roles in several cancers (20-23). In contrast, no studies have 
reported the role of the passenger strand miR-99a-3p in cancer cells. Novel strategies based on 
passenger strands of miRNAs will enhance our understanding of the molecular pathways 
underlying naïve PCa and CRPC pathogenesis. 
 
 
Materials and Methods 
Collection of clinical prostate specimens and cell lines 
Clinical specimens were collected at Teikyo University Chiba Medical Center and Chiba 
University Hospital from 2013 to 2016. Patient characteristics and clinical features are 
summarised in Table 1. The protocol of this study was approved by the Institutional Review 
Boards of Teikyo University and Chiba University. We have experimented with human PCa cell 
lines (PC3, DU145 and C4-2). The cells were maintained as previously reported (11, 15, 24, 
25). 
 
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) 
The procedure of PCR quantification is described in our previous reports. (11, 15, 24-26). 
Expression levels of miR-99a-5p and miR-99a-3p normalized to expression of RNU48 were 
analyzed by TaqMan qRT-PCR. The expression levels of NCAPG and pri-miR-99a were 
assessed by being normalised with GAPDH or GUSB. Detailed product numbers of reagents 
used are shown in the Table S1. 
 
Transfection with mature miRNA, small-interfering RNA (siRNA), or plasmid vectors 
We used the mature miRNAs, siRNAs and plasmid vectors described below: Pre-miR 
miRNA precursor (hsa-miR-99a-5p; assay ID: PM10719 and hsa-miR-99a-3p; assay ID: 
PM12983; Applied Biosystems, Foster City, CA, USA), Stealth Select RNAi siRNAs; si-
NCAPG (cat. nos. HSS127430 and HSS184671; Invitrogen, Carlsbad, CA, USA), and negative 
control miRNA/siRNA (P/N: AM17111; Applied Biosystems). RNAs were incubated with 
OPTI-MEM (Invitrogen) and Lipofectamine RNAiMax reagent (Invitrogen) at a concentration 
of 10 nM by reverse transfection. We used NCAPG plasmid vector designed by ORIGENE (cat. 
no. SC111395; Rockville, MD, USA). Transfection procedures were described as previous 
studies (11, 15, 24-26).  
  
Cell proliferation, migration, and invasion assays 
As functional analyses, cell proliferation, migration, and invasion assays were carried out 
based on our past reports (11, 15, 24-26). We confirmed all experiments in triplicate. 
 
Confirmation of miRNAs incorporated into the RNA-induced silencing complex (RISC) 
by Ago2 immunoprecipitation 
To investigate whether exogenous miR-99a-5p and miR-99a-3p were incorporated into the 
RISC, we carried out immunoprecipitation assays using a microRNA isolation kit for human 
Ago2 (Wako, Osaka, Japan). The procedure is described in our past reports. (11, 15). 
 
Identification strategy of estimated target genes regulated by miR-99a-3p in PCa cells 
To identify putative miR-99a-3p target genes, we used in silico database analyses and 
comprehensive gene expression analyses by microarray technologies, as described previously 
(11, 15, 24-26). The microarray data were deposited into the GEO database 
(https://www.ncbi.nlm.nih.gov/geo/; accession number: GSE85614).  
 
Western blotting 
Immunoblotting was carried out with rabbit anti-NCAPG antibodies (1:750; ab56382; 
Abcam, Cambridge, UK). We used anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
antibodies (1:10000, ab8245; Abcam) for an internal loading control. The experimental 
procedures were performed as described in our past reports (11, 24-26).  
 
Plasmid construction and dual-luciferase reporter assays 
A partial wild type sequence of the NCAPG 3'-untranslated region (UTR) or a sequence 
having a deletion of the miR-99a-3p target site was inserted into the psiCHECK-2 vector 
(C8021; Promega, Madison, Wis., USA). The procedures were reported previously (11, 24-26).  
 
Immunohistochemistry 
Tissue specimens were incubated overnight at 4°C with anti-NCAPG antibodies (1:150; 
ab56382; Abcam). The procedures were described previously (11, 15, 24-26).  
 
The Cancer Genome Atlas (TCGA) database analyses of PCa 
To identify the clinical significance of NCAPG, we applied to TCGA database. The gene 
expression and clinical data were analysed using cBioportal (http://www.cbioportal.org/) (27). 
The data were obtained on May 30, 2017. 
 
Statistical analysis 
The relationship between the 2 groups was analysed using the Mann-Whitney U test. The 
relationship of 3 variables or more was analysed using Bonferroni-adjusted Mann-Whitney U 
tests. The correlation between 2 groups was evaluated by Spearman's rank test. Survival 
analyses by Kaplan-Meier method and log rank test was performed using JMP software (version 
13; SAS Institute Inc., Cary, NC, USA). For all other analyses, Expert StatView (version 5, SAS 
Institute Inc.) was used. 
 
 
Results 
Expression levels of miR-99a-5p and miR-99a-3p in PCa specimens and cell lines 
In human genome, miR-99a is located on chromosome 21q21.1 and the mature sequences 
of miR-99a-5p and miR-99a-3p are 5'-AACCCGUAGAUCCGAUCUUGUG-3 'and 5'-
CAAGCUCGCUUCUAUGGGUCUG-3', respectively (Fig. S1). We validated the expression 
levels of miR-99a-5p and miR-99a-3p in PCa tissues (hormone-sensitive prostate cancer 
[HSPC]: n = 16, CRPC: n = 4), normal tissues (n = 17), and PCa cell lines (PC3, DU145 and 
C4-2). Table 1 shows the patients’ characteristics. The expression levels of miR-99a-5p and 
miR-99a-3p were markedly lower in PCa and CRPC tissues than in normal tissues (miR-99a-5p: 
P = 0.0001 and P < 0.0001, miR-99a-3p: P = 0.0047 and P = 0.0001; Figure 1A and 1B). miR-
99a-5p and miR-99a-3p were expressed with positive correlation. (r = 0.771, P < 0.0001; Figure 
1C). Furthermore, the expression level of pri-miR-99a, a precursor of miR-99a-5p/-3p, was also 
examined and the expression was downregulated in the PCa tissues (Fig. S2). 
 
Both miR-99a-5p and miR-99a-3p bound to Ago2  
To verify that both miR-99a-5p and miR-99a-3p functioned by incorporation into the 
RISC, we performed immunoprecipitation with antibodies targeting Ago2 which plays a key 
role of RISC (Fig. S3A). Quantification of miRNAs bound to Ago2 was detected by PCR 
methods. The amount of miR-99a-5p bound to Ago2 was remarkably higher than that in cells 
transfected with mock, miR-control, and miR-99a-3p (P < 0.0001; Fig. S3B). Similarly, the 
amount of miR-99a-3p bound to Ago2 was markedly higher than that in cells transfected with 
mock, miR-control, and miR-99a-5p (P < 0.0001; Fig. S3B).  
 
Effects of restoring miR-99a-3p on cell proliferation, migration, and invasion activities in 
PCa cell lines  
To confirm the tumor suppressive roles of miR-99a-5p and miR-99a-3p, we carried out 
ectopic expression assays by miRNA transfection into PC3, DU145 and C4-2 cells. According 
to the results of functional assays, cancer cell proliferation, migration activity, and invasion 
activity were all remarkably inhibited by transfection with miR-99a-3p compared with those of 
mock- or miR-control-transfected PC3, DU145 C4-2 cells (P < 0.0001, P < 0.0001, and P < 
0.0001, respectively; Figure 1D-F, Fig. S4A and S4B). Cell proliferation assay was also 
performed in LNCaP cells, and its ability was suppressed by transfection with miR-99a-3p (data 
not shown). In contrast, miR-99a-5p showed no significant antitumor effects (Figure 1D-F).  
 
Search for putative oncogenes regulated by miR-99a-3p in PCa cells 
We focused on miR-99a-3p, which showed marked antitumor effects. The selection 
strategy of miR-99a-3p target genes is shown in Figure 2A. Initially, we used the TargetScan 
Human 7.1 database and found that 1,591 genes had theoretical target sites for miR-99a-3p in 
their 3’-UTRs. Next, we extracted genes whose expression levels were decreased by 
transfection with miR-99a-3p by gene expression analysis (GEO accession number: 
GSE85614). Genes that were markedly decreased by transfection into PC3 cells with miR-99a-
3p are shown in Table 2 (fold-change log2 < -2.0). In this study, a total of 30 putative oncogenic 
targets of miR-99a-3p regulation were identified in PC cells. We investigated further whether it 
has related to the pathogenesis of PCa and these targets by using TCGA database. Among these 
targets, 17 genes (NCAPG, SGOL1, RRM2, ESCO2, ZNF695, CDK1, NEK2, FANCI, FAM64A, 
ZWINT, PIGL, KIF11, MCM4, BRCA1, CDKN3, GRIA2 and MKI67) were involved in PCa 
pathogenesis, high expression of these genes were significantly associated with disease-free 
survival rate (Figure 2B, 3A and 3B).  
Finally, we focused on NCAPG, which showed the greatest reduction in expression 
following transfection with miR-99a-3p.  
 
Clinical significance of NCAPG in PCa 
According to TCGA database, NCAPG expression levels were closely related to prognosis and 
clinical stage in patients with PCa. High NCAPG expression group had remarkably shorter 
disease-free survival (DFS) than that of the low expression group in patients with PCa (P = 
0.0009, Figure 2B). Moreover, the expression levels of NCAPG were markedly increased in 
cases with advanced T stage, advanced N stage, and high Gleason Score (Figure 2C). These 
results indicated that NCAPG may affect disease progression and malignancy in PCa. 
 
NCAPG was directly regulated by miR-99a-3p in PCa cells 
The expression of NCAPG mRNA was significantly decreased by miR-99a-3p 
transfection compared to that of mock- or miR-control-transfected cells (Figure 4A). Consistent 
with this, NCAPG protein expression was reduced by miR-99a-3p transfection (Figure 4B). 
To validate direct binding of miR-99a-3p in NCAPG mRNA, we performed luciferase 
reporter assays. The TargetScan database predicted that miR-99a-3p joined at position 462-468 
in the 3’-UTR of NCAPG. The luminescence intensity was remarkably reduced by co-
transfection with miR-99a-3p and wild-type vector of 3’-UTR of NCAPG. In contrast, using the 
vector in which the target site of miR-99a-3p was deleted, the luminescence intensity did not 
change (Figure 4C). 
 
Expression of NCAPG in PCa clinical specimens 
We evaluated the expression levels of NCAPG in PCa tissues (HSPC: n = 16, CRPC: n = 
4), normal tissues (n = 17), and PCa cell lines (PC3, DU145 and C4-2). NCAPG was markedly 
upregulated in CRPC tissues compared with that in normal tissues and HSPC tissues (P = 
0.0002, P = 0.0018, respectively; Figure 5A). Additionally, Spearman’s rank test indicated that 
miR-99a-3p and NCAPG were expressed with negative correlation. (P = 0.0263, r = -0.370; 
Figure 5B). 
Furthermore, to analyse NCAPG protein expression, immunohistochemistry was 
performed with PCa clinical specimens (Table 1). In CRPC specimens, NCAPG protein was 
strongly expressed in metastatic tissues from patients with CRPC, compared with non-PCa or 
HSPC specimens (Figure 5C and 5D). 
 
Effects of silencing NCAPG in PCa cell lines 
We examined the effects of NCAPG knockdown in PC3, DU145 and C4-2 cells using 2 
types of si-NCAPG (si-NCAPG-1 and si-NCAPG-2). Two siRNAs effectively downregulated 
NCAPG mRNA and NCAPG protein expression in PC3, DU145 and C4-2 cells (Figure 6A and 
6B). Additionally, functional assays indicated that cell proliferation, migration, and invasion 
were significantly inhibited by knockdown of NCAPG in comparison with mock- or si-control-
transfected cells (Figure 6C-E, Fig. S5A and S5B). Even in LNCaP cells, cell proliferation assay 
was performed, and its ability was markedly suppressed by knockdown of NCAPG (data not 
shown). 
 
Effects of cotransfection with NCAPG/miR-99a-3p in PC3 cells  
We performed NCAPG rescue experiments by cotransfection with NCAPG and miR-99a-
3p into PC3 cells. Western blot analysis of NCAPG protein expression is shown in Figure 7A 
and 7B. According to western blotting, NCAPG protein levels were recovered by cotransfection 
with NCAPG and miR-99a-3p in PC3 cells. Moreover, the proliferation, migration, and invasion 
capacities of PC3 cells were recovered by cotransfection with NCAPG and miR-99a-3p 
compared with cells transfected with miR-99a-3p only (Figure 7C-E, Fig. S6A and S6B). These 
results indicated that NCAPG affected the aggressiveness of PC3 cells. 
 
 
Discussion 
One of the main challenges in the treatment of CRPC is the control of aggressive and 
lethal metastatic PCa cells. We believe that identifying genes and pathways involved in 
metastasis and the acquisition of treatment resistance will lead to the development of new 
therapeutic strategies. Based on this background, we have identified several antitumor miRNAs, 
e.g., miR-1, miR-133a, miR-26a, miR-26b, the miR-29 family, miR-205, miR-218, miR-221, 
miR-222, miR-223, and miR-452, and showed that these miRNAs target oncogenes (24, 25, 28-
34). Among these oncogenic genes, the extracellular matrix-related genes laminin γ3 (LAMC3) 
and lysyl oxidase-like 2 (LOXL2) were found to be overexpressed in naïve PCa clinical 
specimens and to enhance cancer cell migration and invasion in PCa cells (30, 31). Moreover, 
integrin α3 (ITGA3) and β1 (ITGB1), heterodimeric transmembrane receptors, were also 
overexpressed in naïve PCa clinical specimens, and integrin-mediated oncogenic signaling 
enhanced cancer cell aggressiveness (25). These molecules are putative therapeutic targets for 
patients with naïve PCa and CRPC. 
In general miRNA biogenesis, guide strand of miRNA is incorporated into RISC (RNA-
induced silencing complex) and acts as a fine-tuner of expression control. In contrast, passenger 
strand of miRNA is disassembled and has no function (17-19). In miRNA biology, miRNA 
strand selection process is still obscure that which strand become the guide strand or the 
passenger strand from a miRNA duplex. Recent studies suggested that the thermodynamic 
character of the duplex seems to play an important role (35). An important feature of the 
miRNA guide strand is the U-bias at the 5 'end and excess purine, and the passenger strand has a 
C-bias at the 5' end and an excess of pyrimidine (35). The molecular dynamics of miRNA 
(guide strand and passenger strand) degradation and stabilization in normal and disease cells 
remain largely unknown. 
Despite the previous theory that passenger strands of miRNA have no function, many 
studies have suggested that some passenger strands have actually functioning in the plant and 
human cells (36-38). Our recent studies showed that some passenger strands of miRNAs, e.g., 
miR-145-3p, miR-149-3p, miR-150-3p, miR-199a-3p and miR-144-5p, acted as anti-tumor 
miRNAs in several types of cancers (11-15). miR-145-5p (guide strand) is known to act as an 
antitumor miRNA in a variety of cancers through targeting several oncogenes (39-41). We 
showed that both strands of pre-miR-145, i.e., miR-145-5p and miR-145-3p, were significantly 
downregulated in CRPC specimens compared with those in naïve PCa or non-PCa specimens 
(15). Our data demonstrated that miR-145-3p (passenger strand) had stronger antitumor effects 
than miR-145-5p (guide strand) in PCa cells (15). We also confirmed the antitumor effects of 
miR-145-3p in bladder and lung and cancers (42, 43). More recently, we showed that both miR-
150-5p (guide strand) and miR-150-3p (passenger strand) acted as antitumor miRNAs through 
targeting SPARC/osteonectin and cwcv and kazal like domains proteoglycan 1 (SPOCK1) in 
naïve PCa and CRPC cells (11). The involvement of passenger strand miRNAs in cellular 
processes regulation is a new conception in RNA research. 
In this study, we focused on miR-99a-5p whose expression was significantly 
downregulated in our miRNA signature of metastatic CRPC, and investigated the functional 
roles including passenger strand miR-99a-3p in PCa cells. As the results, we indicated that miR-
99a-3p has potent antitumor effects in PCa cells. The expression levels of the two miRNAs, 
miR-99a-5p and miR-99a-3p were obviously different in clinical specimens and cancer cell 
lines. We do not see any clear answer as to why this kind of difference will arise. This challenge 
is an important issue for miRNA research. In addition, a more detailed study on the 
concentration of miRNAs to be transfected into cancer cells and anti-tumor effects will be 
necessary. 
The miR-99a-5p (guide strand) has been reported to have tumor-suppressive roles in 
various types of cancers, including PCa (20-23, 44). In non-small cell lung cancer, miR-99a-5p 
was reported to suppress cancer cell proliferation and metastasis by controling the AKT1 
signaling pathway and insulin-like growth factor-1 receptor, which could also serve as a 
diagnostic biomarker (23, 44). Additionally, several recent reports demonstrated the antitumor 
effects of miR-99a-5p on mammalian target of rapamycin (mTOR) regulation (20-22). For 
example, miR-99a-5p directly regulates the mTOR pathway to induce G1-phase cell cycle arrest 
and suppress tumorigenicity in renal cell carcinoma (21). Additionally, in PCa, the miR-99 
family, including miR-99a-5p, directly targets the chromatin-remodeling factors SMARCA5 and 
SMARCD1 and the growth regulatory kinase mTOR, suppresses the expression of PSA, and 
blocks PCa cell proliferation (45). Furthermore, inhibition of the miR-99a/let-7c/miR-125b-2 
miRNA cluster promotes the induction of several androgen-induced genes and stimulates the 
initiation and progression of PCa (46).  
In contrast, the passenger strand miR-99a-3p has been reported as a diagnostic marker of 
the chemotherapy response in patients with advanced colorectal cancer (47); however, there are 
no reports examining the functional significance of miR-99a-3p in cancer cells. Our previous 
studies of miRNA signatures showed that miR-99a-3p was significantly downregulated in 
bladder cancer, renal cell carcinoma and head and neck squamous cell carcinoma, suggesting 
miR-99a-3p has anti-tumor roles in these cancers (48-50). Moreover, TCGA database revealed 
that low expression of miR-99a-3p was significantly associated with poor prognosis in head and 
neck cancer and lung adenocarcinoma (Fig. S7). This is the first report demonstrating that miR-
99-3p may function as an antitumor miRNA in naïve PCa and CRPC cells.  
Unique nature of miRNA, single miRNA controls vast number of genes in normal and 
cancer cells. We performed gene expression analyses and in silico database search to identify 
miR-99a-3p regulated oncogenic genes in PCa cells. Interestingly, a large number of cohort 
analyses by TCGA database showed several targets were deeply involved PCa pathogenesis. 
These genes might be important tools for elucidating the molecular pathogenesis of PCa and 
CRPC. 
In this study, by focusing on miR-99a-3p, which had not been well studied in previous 
reports, we found that NCAPG was directly regulated by miR-99a-3p in PCa cells. 
Overexpression of NCAPG was observed in CRPC clinical specimens, and its expression was 
found to be essential for PCa pathogenesis, as demonstrated by analysis of TCGA database. 
Interestingly, our previous study indicated that NCAPG was regulated by miR-145-3p in PCa 
cells (15). Thus, NCAPG is a candidate gene controlled by multiple antitumor miRNAs in 
CRPC, and its function in the pathogenesis of PCa may be important. However, the cancer-
promoting functions of this molecule are still not well known.  
NCAPG is involved in mitotic chromosome condensation and is related to the cell cycle. 
Mitotic chromosome condensation is an essential cellular property of all proliferating cells and 
results in reconstitution of chromosomes into rod-like mitotic chromosomes, ensuring 
separation of sister chromatids during cell division. In vertebrates, there are two types of 
condensin complexes, type I and II complexes, both of which contain non-structural 
maintenance of chromosomes (non-SMC) regulatory subunits. Defects in one of the subunits 
cause incomplete chromosome condensation (51, 52). NCAPG exists in the condensin I 
complex and is associated with proper segregation of sister chromatids in the condensation and 
fission of mitotic chromosomes (53). Previous studies showed that NCAPG was involved in the 
cell cycle and had cancer-promoting functions in several types of cancer (54, 55). A recent study 
showed that knockdown of NCAPG induced apoptosis, reduced cancer cell survival, and 
suppressed the epithelial-mesenchymal transition (EMT) in cancer cells via upregulation of Bax, 
cleaved caspase-3, and E-cadherin and downregulation of cyclin A1, CDK2, Bcl-2, N-cadherin, 
and HOXB9 in hepatocellular carcinoma (55). Our present data showed that aberrant expression 
of NCAPG enhanced PCa cell aggressiveness. Thus, these data suggested that NCAPG had 
clinical significance in PCa pathogenesis and could have applications as a therapeutic target in 
CRPC. 
In conclusion, both strands of pre-miR-99a, i.e., miR-99a-5p and miR-99a-3p, were 
significantly reduced in naïve PCa and CRPC clinical specimens. The passenger strand, miR-
99a-3p, had potent antitumor effects via targeting of the oncogene NCAPG in PCa cells. 
NCAPG was markedly elevated in CRPC and was involved in CRPC pathogenesis, suggesting 
that NCAPG could have applications as a therapeutic target in CRPC. The involvement of 
passenger strand miRNAs in cancer cells is novel concept of naïve PCa and CRPC 
pathogenesis. 
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Figure legends 
 
Figure 1. Expression of miR-99a-5p/3p in clinical prostate specimens and functional 
analysis of miR-99a-5p/3p in PCa cell lines. 
(A) Expression levels of miR-99a-5p in PCa clinical specimens and cell lines determined using 
qRT-PCR. RNU48 was used as an internal control. (B) Expression levels of miR-99a-5p in PCa 
clinical specimens and cell lines. (C) Correlations among the relative expression levels of miR-
99a-5p and miR-99a-3p. (D-F) Cell proliferation, migration, and invasion assays in cells 
transfected with miR-99a-5p/3p. *P < 0.0001 and **P < 0.001.  
 
Figure 2. Identification of miR-99a-3p target genes and relationship between NCAPG and 
clinicopathological factors. 
(A) Flow chart of the strategy for identification of miR-99a-3p target genes. (B) Kaplan-Meier 
patient survival curves for disease-free survival rates based on NCAPG expression in patients 
with PCa from TCGA database. (C) According to TCGA database, the expression levels of 
NCAPG were significantly increased in cases of advanced T stage, advanced N stage, and high 
Gleason score. *P < 0.01, **P < 0.001, ***P < 0.0001. 
 
Figure 3. Kaplan-Meier survival curves based on expression of 16 genes, excluding 
NCAPG, in patients with PCa. 
Kaplan-Meier patient survival curves for disease-free survival rates based on expression of 16 
genes, excluding NCAPG, in patients with PCa, according to TCGA database. 
 
Figure 4. Direct regulation of NCAPG by miR-99a-3p in PCa cells. 
(A) NCAPG mRNA expression was evaluated using qRT-PCR in PC3, DU145 and C4-2 cells 48 
h after transfection with miR-99a-3p. GAPDH was used as an internal control. *P < 0.0001. (B) 
NCAPG protein expression was evaluated by western blotting in PC3, DU145 and C4-2 cells 72 
h after transfection with miR-99a-3p. (C) miR-99a-3p binding sites in the 3’-UTR of NCAPG 
mRNA. Dual luciferase reporter assays in PC3 using vectors encoding a putative miR-99a-3p 
target site in the NCAPG 3’-UTR (positions 462-468). Data were normalised by expression 
ratios of Renilla/firefly luciferase activities. *P < 0.0001.  
 
Figure 5. Expression of NCAPG in clinical PCa specimens. 
(A) Expression levels of NCAPG in PCa clinical specimens and cell lines. GUSB was used as an 
internal control. (B) The negative correlation between miR-99a-3p and NCAPG. (C) 
Immunochemical staining of NCAPG in HSPC specimens. (D) Immunochemical staining of 
NCAPG in mCRPC specimens.  
 
Figure 6. Effects of NCAPG silencing in PCa cell lines. 
(A) NCAPG mRNA expression was evaluated using qRT-PCR analysis of PC3, DU145 and C4-
2 cells 48 h after transfection with si-NCAPG-1 or si-NCAPG-2. GAPDH was used as an 
internal control. *P < 0.0001. (B) NCAPG protein expression was evaluated by western blot 
analysis of PC3, DU145 and C4-2 cells 72 h after transfection with si-NCAPG-1 or si-NCAPG-
2. GAPDH was used as a loading control. (C-E) Cell proliferation, migration, and invasion 
assays following transfection with si-NCAPG-1 and si-NCAPG-2. *P < 0.0001.  
 
Figure 7. Effects of cotransfection with NCAPG/miR-99a-3p in PCa cell lines. 
(A) NCAPG protein expression was evaluated by western blot analysis of PC3 cells 48 h after 
forward transfection with the NCAPG vector. GAPDH was used as a loading control. (B) 
NCAPG protein expression was evaluated by western blot analysis of PC3 cells 72 h after 
reverse transfection with miR-99a-3p and 48 h after forward transfection with the NCAPG 
vector. (C) Cell proliferation was determined using XTT assays 72 h after reverse transfection 
with miR-99a-3p and 48 h after forward transfection with the NCAPG vector. *P < 0.0001. (D) 
Cell migration activity was assessed by wound-healing assays 48 h after reverse transfection 
with miR-99a-3p and 24 h after forward transfection with the NCAPG vector. **P < 0.001. (E) 
Cell invasion activity was characterized by invasion assays 48 h after reverse transfection with 
miR-99a-3p and 24 h after forward transfection with the NCAPG vector. **P < 0.001. 
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Fig. S1: Schematic representation of the chromosomal location of human miR-99a. 
miR-99a is located on human chromosome 21q21.1. The mature miRNAs miR-99a-5p (guide 
strand) and miR-99a-3p (passenger strand) are derived from pre-miR-99a. 
 
Fig. S2: Expression levels of pri-miR-99a in PCa clinical specimens and cell lines. 
Expression of pri-miR-99a was downregulated in PCa tissues than normal tissues. GUSB was 
used as an internal control. 
 
Fig. S3: Both strands of miR-99a-5p and miR-99a-3p incorporated into the RISC 
(A) Mature miRNAs were transfected into PCa cells and incorporated into the RISC. The 
incorporated miRNAs were prepared with high purity using immunoprecipitation with anti-
human Ago2 monoclonal antibodies. Expression of the miRNAs was quantified with qRT-PCR. 
miR-31-5p was used as an internal control. *P < 0.0001. (B) Expression of miR-99a-5p was 
significantly higher than that in cells transfected with mock, miR control, and miR-99a-3p. 
Likewise, expression of miR-99a-3p was significantly higher than that in cells transfected with 
mock, miR control, and miR-99a-5p. *P < 0.0001. 
 
Fig. S4: Phase micrographs of wound healing and invasion assays following transfection 
with miR-99a-5p/3p in PCa cell lines. 
(A) Phase micrographs of PC3, DU145 and C4-2 cells 24 h after monolayer wound healing. (B) 
Phase micrographs of invading PC3, DU145 and C4-2 cells. 
 
Fig. S5: Phase micrographs of wound healing and invasion assays following transfection 
with si-NCAPG in PCa cell lines. 
(A) Phase micrographs of PC3, DU145 and C4-2 cells 24 h after monolayer wound healing. (B) 
Phase micrographs of invading PC3, DU145 and C4-2 cells. 
 
Fig. S6: Phase micrographs of wound healing and invasion assays following cotransfection 
with NCAPG/miR-99a-3p in PC3 cells. 
(A) Phase micrographs of PC3 cells 24 h after monolayer wound healing. (B) Phase 
micrographs of invading PC3 cells. 
 
Fig. S7: Kaplan-Meier survival curves based on miR-99a-3p expression in patients with 
Head and Neck squamous cell carcinoma and Lung adenocarcinoma. 
Kaplan-Meier curves for overall survival rates (OS) showed that the OS of high miR-99a-3p 
expression group was significantly longer than that of low expression group. Data was extracted 
from OncoLnc website (http://www.oncolnc.org/). 
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Table 1. Patient characteristics
Age PSA
 (years) (ng/mL)
1 Biopsy non-PCa 57 5.71 - - - - - RT-PCR
2 Biopsy non-PCa 74 9.45 - - - - - RT-PCR
3 Biopsy non-PCa 70 8.58 - - - - - RT-PCR
4 Biopsy non-PCa 73 4.8 - - - - - RT-PCR
5 Biopsy non-PCa 67 6.91 - - - - - RT-PCR
6 Biopsy non-PCa 50 7.05 - - - - - RT-PCR
7 Biopsy non-PCa 74 9.91 - - - - - RT-PCR
8 Biopsy non-PCa 76 20.9 - - - - - RT-PCR
9 Biopsy non-PCa 59 4.5 - - - - - RT-PCR
10 Biopsy non-PCa 75 1.1 - - - - - RT-PCR
11 Biopsy non-PCa 60 7.29 - - - - - RT-PCR
12 Biopsy non-PCa 73 38.7 - - - - - RT-PCR
13 Biopsy non-PCa 69 11.9 - - - - - RT-PCR
14 Biopsy non-PCa 77 23.3 - - - - - RT-PCR
15 Biopsy non-PCa 61 4.57 - - - - - RT-PCR
16 Biopsy non-PCa 59 7.37 - - - - - RT-PCR
17 Biopsy non-PCa 65 5.06 - - - - - RT-PCR
18 Biopsy HSPC 70 75.7 4+5 4 1 1 IV RT-PCR
19 Biopsy HSPC 78 1800 4+5 4 1 1 IV RT-PCR
20 Biopsy HSPC 75 68.4 5+4 4 1 0 IV RT-PCR
21 Biopsy HSPC 62 38.7 4+5 2b 1 0 IV RT-PCR
22 Biopsy HSPC 70 25.5 4+5 3b 0 0 III RT-PCR
23 Biopsy HSPC 88 888 4+5 3b 1 1 IV RT-PCR
24 Biopsy HSPC 69 33.9 4+5 4 0 1 IV RT-PCR
25 Biopsy HSPC 62 62.3 4+5 3b 1 0 IV RT-PCR
26 Biopsy HSPC 78 5 4+5 2c 0 1b IV RT-PCR
27 Biopsy HSPC 64 449 4+5 3b 1 1 IV RT-PCR
28 Biopsy HSPC 81 365 4+5 4 1 1 IV RT-PCR
29 Biopsy HSPC 76 715 5+4 4 1 1 IV RT-PCR
30 Biopsy HSPC 79 555 4+5 3 1 1 IV RT-PCR
31 Biopsy HSPC 63 1120 4+5 2c 0 1b IV RT-PCR
32 Biopsy HSPC 67 4.95 4+5 4 1 1b IV RT-PCR
33 Biopsy HSPC 70 19.5 5+5 4 1 1c IV RT-PCR
34 Biopsy CRPC 69 15.8 5+4 3b 1 1 IV RT-PCR
35 Biopsy CRPC 72 212 5+4 4 1 1 IV RT-PCR
36 Biopsy CRPC 71 4.4 4+5 4 1 1 IV RT-PCR
37 Biopsy CRPC 68 7.54 4+5 4 1 1b IV RT-PCR
38 Prostatectomy HSPC 65 5.3 4+5 2a 0 0 II IHC
39 Prostatectomy HSPC 61 21.48 4+4 3a 0 0 III IHC
40 Autopsy CRPC 64 4100 4+5 4 1 1c IV IHC
41 Autopsy CRPC 75 4690 4+5 4 1 1c IV IHC
RemarksPatientNo. Diagnosis T N MProcedure Stage
Gleason
score
Table 2. Putative target genes regulated by miR-99a-3p in PCa cells
Entrez
Gene ID
Gene
Symbol Gene name Location
Number of
miR-99a-3p
target sites
PC3 miR-99a-3p
transfectant
(Log2 ratio)
64151 NCAPG non-SMC condensin I complex, subunit G 4p15.31 1 -3.87
151648 SGOL1 shugoshin-like 1 (S. pombe) 3p24.3 1 -3.49
6241 RRM2 ribonucleotide reductase M2 2p25.1 1 -3.39
157570 ESCO2 establishment of sister chromatid cohesion N-acetyltransferase 2 8p21.1 1 -3.26
57116 ZNF695 zinc finger protein 695 1q44 1 -3.21
113115 MTFR2 mitochondrial fission regulator 2 6q23.3 1 -3.19
983 CDK1 cyclin-dependent kinase 1 10q21.2 1 -3.03
4751 NEK2 NIMA-related kinase 2 1q32.3 1 -2.82
8693 GALNT4 UDP-N-acetyl-alpha-D-galactosamine:polypeptideN-acetylgalactosaminyltransferase 4 (GalNAc-T4) 12q21.33 2 -2.72
143686 SESN3 sestrin 3 11q21 1 -2.61
55215 FANCI Fanconi anemia, complementation group I 15q26.1 1 -2.57
5557 PRIM1 primase, DNA, polypeptide 1 (49kDa) 12q13.3 1 -2.56
54478 FAM64A family with sequence similarity 64, member A 17p13.2 1 -2.56
2218 FKTN fukutin 9q31.2 2 -2.53
51522 TMEM14C transmembrane protein 14C 6p24.2 1 -2.50
11130 ZWINT ZW10 interacting kinetochore protein 10q21.1 1 -2.47
9487 PIGL phosphatidylinositol glycan anchor biosynthesis, class L 17p11.2 1 -2.47
3832 KIF11 kinesin family member 11 10q23.33 1 -2.43
4173 MCM4 minichromosome maintenance complex component 4 8q11.21 1 -2.42
672 BRCA1 breast cancer 1, early onset 17q21.31 1 -2.40
586 BCAT1 branched chain amino-acid transaminase 1, cytosolic 12p12.1 3 -2.38
1033 CDKN3 cyclin-dependent kinase inhibitor 3 14q22.2 1 -2.37
79917 MAGIX MAGI family member, X-linked Xp11.23 1 -2.36
57082 CASC5 cancer susceptibility candidate 5 15q15.1 1 -2.35
2891 GRIA2 glutamate receptor, ionotropic, AMPA 2 4q32.1 1 -2.30
4288 MKI67 antigen identified by monoclonal antibody Ki-67 10q26.2 1 -2.25
283487 LINC00346 long intergenic non-protein coding RNA 346 13q34 1 -2.23
56952 PRTFDC1 phosphoribosyl transferase domain containing 1 10p12.1 1 -2.12
5140 PDE3B phosphodiesterase 3B, cGMP-inhibited 11p15.2 1 -2.04
2177 FANCD2 Fanconi anemia, complementation group D2 3p25.3 1 -2.01
 




Table S1. Product numbers of reagents
Reagant Type Agency Assay ID Catalog nomber
hsa-miR-99a-5p TaqMan MicroRNA Assay Applied Biosystems 000435 4427975
hsa-miR-99a-3p TaqMan MicroRNA Assay Applied Biosystems 002141 4427975
RNU48 TaqMan MicroRNA Assay Applied Biosystems 001006 4427975
has-miR-99a TaqMan Pri-miRNA Assay Applied Biosystems Hs03302729_pri 4427012
NCAPG TaqMan probes and primers Applied Biosystems Hs00254617_m1 4331182
GAPDH TaqMan probes and primers Applied Biosystems Hs02786624_g1 4351370
GUSB TaqMan probes and primers Applied Biosystems Hs00939627_m1 4351370
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